News >

Research Abounds in Targeting Rare Mutations in Lung Cancer

Ellie Leick
Published: Friday, Nov 08, 2019

In the specific drivers we're discussing, which are RET, MET, NTRK, and BRAF, they are somewhat exclusive. However, I was involved in a project where we looked at MET exon 14 splice site alterations and found concurrent KRAS alterations—both de novo and acquired. There is no hard and fast rule to this. We have to question the paradigm that these [mutations] only happen in a vacuum.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication